Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New triple cream takes on melasma in Head-to-Head trial

NCT ID NCT07508098

Disease control Sponsor: Pak Emirates Military Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 4 trial tested whether a triple-combination cream (containing N-acetylcysteine, hydroquinone, and triamcinolone acetate) works better than standard 4% hydroquinone cream for facial melasma. Fifty middle-aged men and women applied one of the creams twice daily for 8 weeks. The main goal was to see how many achieved at least a 60% reduction in their melasma severity score.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Triple combination cream (4.7% N-acetylcysteine, 2% hydroquinone, 0.1% triamcinolone acetate) and 4% hydroquinone cream
What this could lead to
If the triple cream works better, it could offer a more effective topical option for managing melasma with fewer side effects.
What could go wrong
This is a small, single-site study with only 50 participants, so results may not apply to everyone. Melasma often requires ongoing treatment, and any improvement may not be permanent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

50 people

The number who actually took part.

Started

Jul 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patient with facial melasma of age between 15 years to 45 years of both gender Exclusion Criteria: * patient who have already taken treatment within 8 weeks, pregnant women, who are taking hormonals therapy and patient of dementia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melasma (facial melasma) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Melanosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melasma (facial melasma)

Contacts and locations

Locations

  • Dermatology Department of Tertiary Care Hospital

    Rawalpindi, Punjab Province, 46000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.